

Special Issue

Genetics and Clinicopathological Features in Retinal Diseases: Opportunities and Progress

Message from the Guest Editor

Understanding the underlying genetics behind various retinal diseases will pave the way for the future of precision medicine. As early as the 1970s, the first proof of principle *ex vivo* experiments has led to the proposal that gene therapy could be used to treat inherited monogenic disorders. The eye is a unique target as it is relatively immune-privileged. In 2017, the FDA first approved Voretigene Neparvovec for the treatment of bi-allelic RPE65 mutation associated retinal dystrophy. This Special Issue aims to provide a platform and forum for scientists to showcase their research, ideas and novel findings. We aim to gather contributions from all aspects related to the genetics and clinical findings in retinal diseases that. We hope to increase the knowledge base in relation to this topic.

Guest Editor

Dr. Andrew S.H. Tsai

Singapore National Eye Centre, Singapore City, Singapore

Deadline for manuscript submissions

closed (31 December 2023)



Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



mdpi.com/si/166077

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)





Diagnostics

an Open Access Journal
by MDPI

Impact Factor 3.3
CiteScore 5.9
Indexed in PubMed



[mdpi.com/journal/
diagnostics](https://mdpi.com/journal/diagnostics)



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer
Department of Clinical Physiology, Nuclear Medicine & PET National
University Hospital, Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).